Savings from the introduction of BPaL and BPaLM regimens at the country level

Savings from the introduction of BPaL and BPaLM regimens at the country level

BACKGROUND: In 2022, the WHO recommended the 6-month regimens BPaL (bedaquiline + pretomanid + linezolid) and BPaLM (BPaL + moxifloxacin) as treatment options for most forms of drug-resistant TB. SLASH-TB estimates the cost-saving and cost-effectiveness for the healthcare system and patients when a...

Full description

Saved in:
Bibliographic Details
Main Authors: C. Auer, A. Gupta, C. Malbacius, A. Ghafoor, Y. Kock, O. Medvedieva, P. Hanlon, P. Steinmann, S. Juneja
Format: Article
Language:English
Published: International Union Against Tuberculosis and Lung Disease (The Union) 2024-07-01
Series:IJTLD Open
Subjects:
drug-resistant tb treatment
six-month regimens
cost savings
bedaquiline
pretomanid
economic evaluation
cost analysis
Online Access:https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000007/art00006
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items